Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Pulmatrix reported a Q2 net loss of $1.0 million with cash and equivalents declining to $2.2 million from $4.1 million at year-end 2025. The company stated that all clinical development remains on hold while it seeks to monetize or out-license its assets. Management filed a Form S-4 registration statement regarding the proposed merger with Eos SENOLYTIX, which is expected to close in the third quarter of 2026. The company disclosed that its financial statements were prepared on a going concern basis, relying on the successful consummation of this merger.
Key figures
- Cash balance
- 2200000
- Rnd expenses
- <$0.1 million
- Restricted cash
- 700000
- G and a expenses
- 1000000
- Financing proceeds
- 1000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.